Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | OPRK1 | P41145 | 1/20 | 0.62 |
| ▸ | MAPT | P10636 | 2/20 | 0.59 |
| ▸ | BCHE | P06276 | 3/20 | 0.53 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.50 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.50 |
| ▸ | TDP1 | Q9NUW8 | 2/20 | 0.50 |
| ▸ | MEN1 | O00255 | 6/20 | 0.48 |
| ▸ | KMT2A | Q03164 | 6/20 | 0.48 |
| ▸ | L3MBTL1 | Q9Y468 | 2/20 | 0.48 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.48 |
| ▸ | PKM | P14618 | 2/20 | 0.47 |
| ▸ | GAA | P10253 | 1/20 | 0.46 |
| ▸ | HTR2A | P28223 | 1/20 | 0.45 |
| ▸ | LMNA | P02545 | 1/20 | 0.45 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6093321 | 1.00 | OPRK1 (0.62) | OPRK1MAPTBCHEALDH1A1KDM4E | |
| SCHEMBL6095014 | 0.88 | KMT2A (0.62) | MAPTBCHEALDH1A1KDM4ETDP1 | |
| SCHEMBL6092685 | 0.88 | KMT2A (0.62) | MAPTBCHEALDH1A1KDM4ETDP1 | |
| SCHEMBL6092690 | 0.88 | KMT2A (0.62) | MAPTBCHEALDH1A1KDM4ETDP1 | |
| SCHEMBL6267569 | 0.85 | OPRK1 (0.60) | OPRK1MAPTALDH1A1KDM4ETDP1 | |
| SCHEMBL6267565 | 0.85 | OPRK1 (0.60) | OPRK1MAPTALDH1A1KDM4ETDP1 | |
| SCHEMBL6094415 | 0.82 | L3MBTL1 (0.55) | BCHEKDM4EMEN1KMT2AL3MBTL1 | |
| SCHEMBL6094413 | 0.82 | L3MBTL1 (0.55) | BCHEKDM4EMEN1KMT2AL3MBTL1 | |
| SCHEMBL6272264 | 0.82 | L3MBTL1 (0.55) | BCHEKDM4EMEN1KMT2AL3MBTL1 | |
| SCHEMBL6095230 | 0.81 | BCHE (0.50) | OPRK1BCHEALDH1A1KDM4EMEN1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7078565-B2 | Benzamide derivatives as antagonists of orexin receptors | SMITHKLINE BEECHAM PLC (GB) | 2006-07-18 | — | — | US | disclosed |
| EP-1440052-B1 | BENZAMIDE DERIVATIVES AS ANTAGONISTS OF OREXIN RECEPTORS | SMITHKLINE BEECHAM PLC (GB) | 2005-12-14 | — | — | EP | disclosed |
| US-20050020584-A1 | Benzamide derivatives as antagonists of orexin receptors | SMITHKLINE BEECHAM P.L.C. (GB) | 2005-01-27 | — | — | US | disclosed |
| EP-1440052-A1 | BENZAMIDE DERIVATIVES AS ANTAGONISTS OF OREXIN RECEPTORS | SMITHKLINE BEECHAM PLC (GB) | 2004-07-28 | — | — | EP | disclosed |
| WO-2003037847-A1 | BENZAMIDE DERIVATIVES AS ANTAGONISTS OF OREXIN RECEPTORS | SMITHKLINE BEECHAM P.L.C. (GB) | 2003-05-08 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050020584-A1 | Benzamide derivatives as antagonists of orexin receptors | HCRTR2, HCRTR1, OXTR | OPRK1 166/4885MAPT 1412/4885BCHE 440/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.